1. Home
  2. LSF vs LNAI Comparison

LSF vs LNAI Comparison

Compare LSF & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Laird Superfood Inc.

LSF

Laird Superfood Inc.

HOLD

Current Price

$3.34

Market Cap

23.8M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.80

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LSF
LNAI
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.8M
20.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
LSF
LNAI
Price
$3.34
$0.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
124.1K
188.7K
Earning Date
02-25-2026
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,146,862.00
N/A
Revenue This Year
$18.05
N/A
Revenue Next Year
$17.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.73
N/A
52 Week Low
$1.98
$0.75
52 Week High
$8.26
$14.00

Technical Indicators

Market Signals
Indicator
LSF
LNAI
Relative Strength Index (RSI) 61.78 36.58
Support Level $3.07 $0.79
Resistance Level $3.62 $0.97
Average True Range (ATR) 0.33 0.09
MACD 0.07 -0.00
Stochastic Oscillator 73.88 16.99

Price Performance

Historical Comparison
LSF
LNAI

About LSF Laird Superfood Inc.

Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: